Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.19.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Income Statement [Abstract]      
Revenues $ 460,739 $ 88,691 $ 67,678
Other income 10,403
Total revenues 460,739 88,691 78,081
Cost of revenues 388,265 94,238 78,622
Amortization of intangible assets 470,773 37,694
Gross loss 398,299 43,241 541
Operating expenses:      
Research and development 1,090,295 787,025 976,882
Less - research and development grants (314,652) (382,134) (344,056)
Research and development, net 775,643 404,891 632,826
Sales and marketing 550,008 480,963 336,287
General and administrative 1,297,711 1,227,632 571,110
Goodwill impairment 161,381  
Acquisition related costs 750,956
Total operating expenses 2,784,743 2,864,442 1,540,223
Operating loss 3,183,042 2,907,683 1,540,764
Financial (income) expenses, net (1,210,484) (63,778) 80,636
Net loss $ 1,972,558 $ 2,843,905 $ 1,621,400
Net loss per ordinary share:      
Basic and diluted net loss per ordinary share $ 0.09 $ 0.19 $ 0.12
Weighted average number of ordinary shares used in computing basic and diluted net loss per ordinary share 23,142,850 15,249,947 13,704,673